Christopher Clinton Conway, Chief Philanthropy, Communications & Strategic Partnerships Officer at Indiana Biosciences Research Institute (IBRI), shared on LinkedIn:
“The future of life sciences innovation will depend on new partnerships between science, philanthropy, and investment.
Europe faces a significant research funding challenge. In the most recent year for which data are available, EU investment in R/D reached just 2.24% of GDP, well below its 3% target. Yet philanthropy contributed more than €5 billion to European research and innovation.
Encouragingly, the Gates Foundation, Novo Nordisk Foundation, and the Wellcome Trust are partnering in a series of European dialogues continuing through the end of 2026 and throughout 2027, exploring how philanthropic capital can work alongside government and private investment to accelerate scientific discovery.
At the Indiana Biosciences Research Institute (IBRI), we are advancing a similar vision by connecting science, philanthropy, and industry to accelerate innovation and commercialization here in BioHeartland Indiana.
I look forward to continuing this conversation at BIO-Europe in Cologne, Germany, November 4-11, exploring new opportunities for transatlantic collaboration.
Innovation knows no borders. Neither should philanthropy.”
Other articles featuring Christopher Clinton Conway on OnocDaily.